Using an advanced MRI scan to guide prostate biopsy and help find prostate cancer
Tests whether an advanced MRI can help find prostate cancer during biopsy.
Plain-language title generated from the registry record
Registry title: CEST for Prostate Biopsy
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Sunnybrook Health Sciences CentreToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sunnybrook Health Sciences Centre
- Trial code
- NCT07785024
- Record updated
- 25 August 2026
- Original description
Samples of prostate tissue acquired by biopsy to determine whether there is cancer will sometimes not find cancer that is present. Conventionally, magnetic resonance imaging (MRI) is used to identify 12 areas to biopsy. We will use an advanced MRI method called magnetization transfer (MT) and chemical exchange saturation transfer (CEST) imaging to suggest two additional biopsy location. Our objectives are to determine 1) whether MT/CEST MRI can aid in the detection prostate cancer and 2) whether MT/CEST MRI can aid conventional MRI in risk stratification and to decide whether targeted prostate biopsy is justified.Read full original descriptionShow less
Advanced Metabolic MRI to Refine Targeted Prostate Biopsy
Samples of prostate tissue acquired by biopsy to determine whether there is cancer will sometimes not find cancer that is present. Conventionally, magnetic resonance imaging (MRI) is used to identify 12 areas to biopsy. We will use an advanced MRI method called magnetization transfer (MT) and chemical exchange saturation transfer (CEST) imaging to suggest two additional biopsy location. Our objectives are to determine 1) whether MT/CEST MRI can aid in the detection prostate cancer and 2) whether MT/CEST MRI can aid conventional MRI in risk stratification and to decide whether targeted prostate biopsy is justified.
Inclusion: PI-RADS category 3 prostate cancer with upcoming targeted biopsy.
Exclusion: Prior radiotherapy; Prior chemotherapy; Prior prostate biopsy; Contraindications to MRI.